| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2b94e8ed234ad484c5475ddd7b91302f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1d129195d35f178edd75fb75e7d8f5fd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87a3e83ed3ab0831df820ee4529ea450 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-203
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24032 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate |
2021-02-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b28e7e3bedf5f7c8b95431270f26521
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8a9407c65d1d50217b66255005c9947
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7cefdccc74cd32747580cc66bffa9aae |
| publicationDate |
2022-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-4106781-A1 |
| titleOfInvention |
Recombinant myxoma viruses and uses thereof |
| abstract |
The present disclosure provides a recombinant oncolytic myxoma virus engineered to express a soluble form of an immune checkpoint protein in conjunction with a cytokine/chemokine and/or a tumor antigen. In certain aspects, the oncolytic myxoma virus is a replication competent virus such as myxoma virus. Methods of cancer treatment comprising administering the recombinant oncolytic myxoma virus expressing the soluble form of the immune checkpoint protein are also provided. |
| priorityDate |
2020-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |